Terms: = Breast cancer AND ACVR1, SKR1, 90, ENSG00000115170, Q04771, ACVRLK2, FOP, ALK2, ACTRI AND Clinical Outcome
144 results:
1. Molecular features of luminal breast cancer defined through spatial and single-cell transcriptomics.
Yoshitake R; Mori H; Ha D; Wu X; Wang J; Wang X; Saeki K; Chang G; Shim HJ; Chan Y; Chen S
Clin Transl Med; 2024 Jan; 14(1):e1548. PubMed ID: 38282415
[TBL] [Abstract] [Full Text] [Related]
2. Adrenal incidentalomas, cortisol secretion and cancer: is there a real crosstalk?
Herrera-Martínez AD; Román ÁR; Corrales EP; Idrobo C; Ramírez PP; Rojas PM; Lázaro CR; Araujo-Castro M
Front Endocrinol (Lausanne); 2023; 14():1335202. PubMed ID: 38264281
[TBL] [Abstract] [Full Text] [Related]
3. Genetic Ancestry-specific Molecular and Survival Differences in Admixed Patients With breast cancer.
Telonis AG; Rodriguez DA; Spanheimer PM; Figueroa ME; Goel N
Ann Surg; 2024 May; 279(5):866-873. PubMed ID: 38073557
[TBL] [Abstract] [Full Text] [Related]
4. A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic breast cancer.
Cescon DW; Hilton J; Morales Murilo S; Layman RM; Pluard T; Yeo B; Park IH; Provencher L; Kim SB; Im YH; Wyce A; Krishnatry AS; Hicks K; Zhang Q; Barbash O; Khaled A; Horner T; Dhar A; Oliveira M; Sparano JA
Clin Cancer Res; 2024 Jan; 30(2):334-343. PubMed ID: 37992310
[TBL] [Abstract] [Full Text] [Related]
5. Clinicopathological and prognostic value of TIL and PD L1 in triple negative breast carcinomas.
Uğurluoğlu C; Yormaz S
Pathol Res Pract; 2023 Oct; 250():154828. PubMed ID: 37778126
[TBL] [Abstract] [Full Text] [Related]
6. Construction of a Matrix cancer-Associated Fibroblast Signature Gene-Based Risk Prognostic Signature for Directing Immunotherapy in Patients with breast cancer Using Single-Cell Analysis and Machine Learning.
Huang B; Chen Q; Ye Z; Zeng L; Huang C; Xie Y; Zhang R; Shen H
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685980
[TBL] [Abstract] [Full Text] [Related]
7. Pathological complete response rate and clinical outcome after neoadjuvant therapy of HER2-low breast cancer: A National cancer Database Analysis.
Zhong G; Song D; Lou W; Wei B; Chen Y; Cui H; Hu J; Dong H; Chen J; Dai Z
Eur J Surg Oncol; 2023 Nov; 49(11):106970. PubMed ID: 37365055
[TBL] [Abstract] [Full Text] [Related]
8. Bioinformatics identification and validation of aging‑related molecular subtype and prognostic signature in breast cancer.
Li J; Gao F; Su J; Pan T
Medicine (Baltimore); 2023 May; 102(19):e33605. PubMed ID: 37171324
[TBL] [Abstract] [Full Text] [Related]
9. The clinical outcome of postoperative radiotherapy using hybrid planning technique in left breast cancer after breast-conserving surgery.
Wei TN; Yeh HL; Lin JF; Hung CC
Cancer Med; 2023 Mar; 12(5):5364-5371. PubMed ID: 36250354
[TBL] [Abstract] [Full Text] [Related]
10. clinical characteristics and prognostic nomogram for patients with insular thyroid carcinoma: a population-based analysis.
Yin L; Hou S; Hou LL; Pu CC
Endocrine; 2023 Feb; 79(2):331-341. PubMed ID: 36207552
[TBL] [Abstract] [Full Text] [Related]
11. Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial.
Capoluongo ED; Pellegrino B; Arenare L; Califano D; Scambia G; Beltrame L; Serra V; Scaglione GL; Spina A; Cecere SC; De Cecio R; Normanno N; Colombo N; Lorusso D; Russo D; Nardelli C; D'Incalci M; Llop-Guevara A; Pisano C; Baldassarre G; Mezzanzanica D; Artioli G; Setaro M; Tasca G; Roma C; Campanini N; Cinieri S; Sergi A; Musolino A; Perrone F; Chiodini P; Marchini S; Pignata S
ESMO Open; 2022 Oct; 7(5):100585. PubMed ID: 36156447
[TBL] [Abstract] [Full Text] [Related]
12. Conservative interventions and clinical outcome measures used in the perioperative rehabilitation of breast cancer patients undergoing mastectomy: a scoping review.
Mathieu J; Daneau C; Lemeunier N; Doyon A; Marchand AA; Descarreaux M
BMC Womens Health; 2022 Aug; 22(1):343. PubMed ID: 35974334
[TBL] [Abstract] [Full Text] [Related]
13. Does concomitant ductal carcinoma in situ affect the clinical outcome in breast cancer patients with invasive ductal carcinoma: An Asian perspective.
Lee WP; Shetty SS; Seah CMJ; Tan PT; Tan SM
Cancer Rep (Hoboken); 2022 Sep; 5(9):e1646. PubMed ID: 35892151
[TBL] [Abstract] [Full Text] [Related]
14. HSP90 N-terminal inhibitors target oncoprotein MORC2 for autophagic degradation and suppress MORC2-driven breast cancer progression.
Yang F; Sun R; Hou Z; Zhang FL; Xiao Y; Yang YS; Yang SY; Xie YF; Liu YY; Luo C; Liu GY; Shao ZM; Li DQ
Clin Transl Med; 2022 May; 12(5):e825. PubMed ID: 35522895
[TBL] [Abstract] [Full Text] [Related]
15. Phase II Study of Taselisib in
Krop IE; Jegede OA; Grilley-Olson JE; Lauring JD; Mitchell EP; Zwiebel JA; Gray RJ; Wang V; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Kono SA; Ford JM; Garcia AA; Sui XD; Siegel RD; Slomovitz BM; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
JCO Precis Oncol; 2022 Feb; 6():e2100424. PubMed ID: 35138919
[TBL] [Abstract] [Full Text] [Related]
16. Hypofractionated radiotherapy in ten fractions for postmastectomy patients: a phase II study compared with another hypofractionation schedule with sixteen fractions.
Jiang H; Meng L; Zhang H; Dai X; Zhang Q; Ju Z; Yu W; Ma L
BMC Cancer; 2021 Dec; 21(1):1284. PubMed ID: 34852776
[TBL] [Abstract] [Full Text] [Related]
17. Tumor-infiltrating lymphocytes predict improved overall survival after post-mastectomy radiotherapy: a study of the randomized DBCG82bc cohort.
Tramm T; Vinter H; Vahl P; Özcan D; Alsner J; Overgaard J
Acta Oncol; 2022 Feb; 61(2):153-162. PubMed ID: 34705573
[TBL] [Abstract] [Full Text] [Related]
18. The survival time of end-of-life home care patients in Fukui prefecture, Japan: A retrospective observational study.
Kosaka M; Miyatake H; Kotera Y; Masunaga H; Arita S; Tsunetoshi C; Nishikawa Y; Ozaki A; Beniya H
Medicine (Baltimore); 2021 Sep; 100(38):e27225. PubMed ID: 34559116
[TBL] [Abstract] [Full Text] [Related]
19. Targeting KDM4B that coactivates c-Myc-regulated metabolism to suppress tumor growth in castration-resistant prostate cancer.
Wu MJ; Chen CJ; Lin TY; Liu YY; Tseng LL; Cheng ML; Chuu CP; Tsai HK; Kuo WL; Kung HJ; Wang WC
Theranostics; 2021; 11(16):7779-7796. PubMed ID: 34335964
[No Abstract] [Full Text] [Related]
20. Combined Estrogen Receptor and Progesterone Receptor Level Can Predict Survival outcome in Human Epidermal Growth Factor Receptor 2-positive Early breast cancer.
Chen M; Wu J; Liu D; Chen W; Lin C; Andriani L; Ding S; Huang O; He J; Chen X; Chen W; Li Y; Shen K; Zhu L
Clin Breast Cancer; 2022 Feb; 22(2):e147-e156. PubMed ID: 34244052
[TBL] [Abstract] [Full Text] [Related]
[Next]
